A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

P. G. Corrie; P. Terheyden; A. J. ten Tije; R. Herbst; R. Jansen; M. Marples; D. Debus; R. Marconcini; M. Blasinska-Morawiec; K. Freivogel; M. L. G. Munson; G. R. Goodman; J. J. Hsu; N. Sadetsky; D. Colburn; P. Rutkowski

doi:10.1111/bjd.17465

A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

P. G. Corrie^*, P. Terheyden, A. J. ten Tije, R. Herbst, R. Jansen, M. Marples, D. Debus, R. Marconcini, M. Blasinska-Morawiec, K. Freivogel, M. L. G. Munson, G. R. Goodman, J. J. Hsu, N. Sadetsky, D. Colburn, P. Rutkowski

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1254-1255
Number of pages	2
Journal	British Journal of Dermatology
Volume	180
Issue number	5
DOIs	https://doi.org/10.1111/bjd.17465
Publication status	Published - May 2019

Keywords

COBIMETINIB
SURVIVAL

Access to Document

10.1111/bjd.17465

Cite this

Corrie, P. G., Terheyden, P., ten Tije, A. J., Herbst, R., Jansen, R., Marples, M., Debus, D., Marconcini, R., Blasinska-Morawiec, M., Freivogel, K., Munson, M. L. G., Goodman, G. R., Hsu, J. J., Sadetsky, N., Colburn, D., & Rutkowski, P. (2019). A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). British Journal of Dermatology, 180(5), 1254-1255. https://doi.org/10.1111/bjd.17465

@article{285e666c244b4ff283faaa521db12074,

title = "A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)",

keywords = "COBIMETINIB, SURVIVAL",

author = "Corrie, {P. G.} and P. Terheyden and {ten Tije}, {A. J.} and R. Herbst and R. Jansen and M. Marples and D. Debus and R. Marconcini and M. Blasinska-Morawiec and K. Freivogel and Munson, {M. L. G.} and Goodman, {G. R.} and Hsu, {J. J.} and N. Sadetsky and D. Colburn and P. Rutkowski",

note = "Funding Information: This study was sponsored by F. Hoffmann-La Roche Ltd. Medical writing assistance was provided by Lucy Smithers (ApotheCom, San Francisco, CA, U.S.A.) and was funded by F. Hoffmann-La Roche Ltd.",

year = "2019",

month = may,

doi = "10.1111/bjd.17465",

language = "English",

volume = "180",

pages = "1254--1255",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley",

number = "5",

}

Corrie, PG, Terheyden, P, ten Tije, AJ, Herbst, R, Jansen, R, Marples, M, Debus, D, Marconcini, R, Blasinska-Morawiec, M, Freivogel, K, Munson, MLG, Goodman, GR, Hsu, JJ, Sadetsky, N, Colburn, D & Rutkowski, P 2019, 'A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)', British Journal of Dermatology, vol. 180, no. 5, pp. 1254-1255. https://doi.org/10.1111/bjd.17465

A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study). / Corrie, P. G.; Terheyden, P.; ten Tije, A. J. et al.
In: British Journal of Dermatology, Vol. 180, No. 5, 05.2019, p. 1254-1255.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - A prospective observational safety study of patients with BRAF(V600)-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

AU - Corrie, P. G.

AU - Terheyden, P.

AU - ten Tije, A. J.

AU - Herbst, R.

AU - Jansen, R.

AU - Marples, M.

AU - Debus, D.

AU - Marconcini, R.

AU - Blasinska-Morawiec, M.

AU - Freivogel, K.

AU - Munson, M. L. G.

AU - Goodman, G. R.

AU - Hsu, J. J.

AU - Sadetsky, N.

AU - Colburn, D.

AU - Rutkowski, P.

N1 - Funding Information: This study was sponsored by F. Hoffmann-La Roche Ltd. Medical writing assistance was provided by Lucy Smithers (ApotheCom, San Francisco, CA, U.S.A.) and was funded by F. Hoffmann-La Roche Ltd.

PY - 2019/5

Y1 - 2019/5

KW - COBIMETINIB

KW - SURVIVAL

U2 - 10.1111/bjd.17465

DO - 10.1111/bjd.17465

M3 - Comment/Letter to the editor

C2 - 30488430

SN - 0007-0963

VL - 180

SP - 1254

EP - 1255

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 5

ER -